Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase NA 1Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 60Sarcoma 9Endocrine 3Thoracic 2NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2267Lung Neoplasms 1050Small Cell Lung Carcinoma 403Adenocarcinoma of Lung 155Mesothelioma, Malignant 120Breast Neoplasms 110Neoplasms 106Brain Neoplasms 101Neoplasm Metastasis 95Melanoma 72Mesothelioma 70NSCLC 69Colorectal Neoplasms 69Adenocarcinoma, Bronchiolo-Alveolar 56Thymoma 53Pancreatic Neoplasms 52Head and Neck Neoplasms 47Ovarian Neoplasms 46Carcinoma, Renal Cell 43Carcinoma 39Stomach Neoplasms 36Prostatic Neoplasms 36Sarcoma 35Esophageal Neoplasms 35Uterine Cervical Neoplasms 34Squamous Cell Carcinoma of Head and Neck 34Adenocarcinoma 34Pleural Effusion, Malignant 33Recurrence 27Urinary Bladder Neoplasms 26

Interventions

fludarabine phosphate 1fludarabine 1aldesleukin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Meningioma × Thoracic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT01849484 2016-08-01

HIPPO-SPARE 01

University of Erlangen-Nürnberg Medical School

Phase 2 Unknown
150 enrolled
CNSEndocrineThoracic

Brain Neoplasms, Meningioma, Pituitary Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡